Ceramide mediates nanovesicle shedding and cell death in response to phosphatidylinositol ether lipid analogs and perifosine

Cell Death and Disease

Volumn 3, Issue 7, 2012, Pages

  Gills, J J ^a   Zhang, C ^a   Abu Asab, M S ^a   Castillo, S S ^b   Marceau, C ^a   LoPiccolo, J ^a   Kozikowski, A P ^c   Tsokos, M ^a   Goldkorn, T ^b   Dennis, P A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Akt; ceramide; nanovesicle; perifosine; sphingomyelinase

Indexed keywords

ALKYLPHOSPHOLIPID; CERAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; PERIFOSINE; PHOSPHATIDYLINOSITOL ETHER LIPID ANALOG; PHOSPHOLIPID; PHOSPHOLIPID DERIVATIVE; PROTEIN KINASE B; SOMATOMEDIN RECEPTOR; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELIN PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ETHYL 7 (3 NITROPHENYL) 5,8A DIMETHYL 6 METHOXYCARBONYL 2,3,8,8A TETRAHYDRO 7H OXAZOLO(3,2 A)PYRIDIN 8 CARBOXYLATE; ETHYL-7-(3-NITROPHENYL)-5,8A-DIMETHYL-6-METHOXYCARBONYL-2,3,8,8A-TETRAHYDRO-7H-OXAZOLO(3,2-A)PYRIDIN-8-CARBOXYLATE; PHOSPHORYLCHOLINE; POLYPHOSPHOINOSITIDE; PYRIDINE DERIVATIVE; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CELL VACUOLE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LUNG NON SMALL CELL CANCER; MEDIATOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECIPIENT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; SECRETORY VESICLE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CERAMIDES; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; PHOSPHATIDYLINOSITOL PHOSPHATES; PHOSPHORYLCHOLINE; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RNA INTERFERENCE; RNA, SMALL INTERFERING; SECRETORY VESICLES; SPHINGOMYELIN PHOSPHODIESTERASE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84864886654     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.72     Document Type: Article

References (42)

1. Castillo SS, Brognard J, Petukhov PA, Zhang C, Tsurutani J, Granville CA et al. Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res 2004; 64: 2782-2792.
2. Gills JJ, Castillo SS, Zhang C, Petukhov PA, Memmott RM, Hollingshead M et al. Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms. J Biol Chem 2007; 282: 27020-27029.
3. Memmott RM, Gills JJ, Hollingshead M, Powers MC, Chen Z, Kemp B et al. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. Cancer Res 2008; 68: 580-588.
4. Zhang C, Elkahloun AG, Liao H, Delaney S, Saber B, Morrow B et al. Expression signatures of the lipid-based akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. Mol Cancer Ther 2011; 10: 1137-1148.
5. Gills JJ, Holbeck S, Hollingshead M, Hewitt SM, Kozikowski AP, Dennis P.A. Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol Cancer Ther 2006; 5: 713-722.
6. Gills JJ, Dennis P.A. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009; 11: 102-110.
7. Adam RM, Mukhopadhyay NK, Kim J, Di Vizio D, Cinar B, Boucher K et al. Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res 2007; 67: 6238-6246.
8. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze H.J. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem 1998; 273: 20121-20127.
9. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman M.R. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005; 115: 959-968.
10. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008; 319: 1244-1247.
11. Zeidan YH, Jenkins RW, Hannun Y.A. Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway. J Cell Biol 2008; 181: 335-350.
12. Wu BX, Clarke CJ, Matmati N, Montefusco D, Bartke N, Hannun Y.A. Identification of novel anionic phospholipid binding domains in neutral sphingomyelinase 2 with selective binding preference. J Biol Chem 2011; 286: 22362-22371.
13. Van Der Luit AH, Budde M, Zerp S, Caan W, Klarenbeek JB, Verheij M et al. Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts. Biochem J 2007; 401: 541-549.
14. David E, Sinha R, Chen J, Sun SY, Kaufman JL, Lonial S. Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clin Cancer Res 2008; 14: 5090-5098.
15. Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, Chiarini F et al. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res 2008; 68: 9394-9403.
16. Sun H, Yu T, Li J. Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: More than just AKT inhibition. Cancer Lett 2011; 310: 118-128.
17. Fu L, Kim YA, Wang X, Wu X, Yue P, Lonial S et al. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res 2009; 69: 8967-8976.
18. van Der Luit AH, Vink SR, Klarenbeek JB, Perrissoud D, Solary E, Verheij M et al. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther 2007; 6: 2337-2345.
19. Gajate C, Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007; 109: 711-719.
20. de Gassart A, Geminard C, Fevrier B, Raposo G, Vidal M. Lipid raft-associated protein sorting in exosomes. Blood 2003; 102: 4336-4344.
21. Schorey JS, Bhatnagar S. Exosome function: from tumor immunology to pathogen biology. Traffic 2008; 9: 871-881.
22. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak M.Z. Membranederived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006; 20: 1487-1495.
23. Bianco F, Perrotta C, Novellino L, Francolini M, Riganti L, Menna E et al. Acid sphingomyelinase activity triggers microparticle release from glial cells. EMBO J 2009; 28: 1043-1054.
24. Herz J, Pardo J, Kashkar H, Schramm M, Kuzmenkina E, Bos E et al. Acid sphingomyelinase is a key regulator of cytotoxic granule secretion by primary T lymphocytes. Nat Immunol 2009; 10: 761-768.
25. Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005; 65: 2422-2432.
26. Rios-Marco P, Jimenez-Lopez JM, Marco C. Segovia JL, Carrasco M.P. Antitumoral alkylphospholipids induce cholesterol efflux from the plasma membrane in HepG2 cells. J Pharmacol Exp Ther 2011; 336: 866-873.
27. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008; 10: 619-624.
28. Nazarenko I, Rana S, Baumann A, McAlear J, Hellwig A, Trendelenburg M et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res 2010; 70: 1668-1678.
29. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci USA 2009; 106: 3794-3799.
30. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001; 7: 297-303.
31. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998; 4: 594-600.
32. Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005; 3: 9.
33. Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 2005; 4: 1595-1604.
34. Yu X, Harris SL, Levine A.J. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res 2006; 66: 4795-4801.
35. Zhou H, Pisitkun T, Aponte A, Yuen PS, Hoffert JD, Yasuda H et al. Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int 2006; 70: 1847-1857.
36. Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C. Exosomal-like vesicles are present in human blood plasma. Int Immunol 2005; 17: 879-887.
37. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002; 360: 295-305.
38. Runz S, Keller S, Rupp C, Stoeck A, Issa Y, Koensgen D et al. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol 2007; 107: 563-571.
39. Saddoughi SA, Garrett-Mayer E, Chaudhary U, O'Brien PE, Afrin LB, Day TA et al. Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum c18-ceramide as a novel biomarker for monitoring response. Clin Cancer Res 2011; 17: 6097-6105.
40. Kozikowski AP, Sun H, Brognard J, Dennis PA, Novel P.I. analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J Am Chem Soc 2003; 125: 1144-1145.
41. Canman CE, Wolff AC, Chen CY, Fornace Jr AJ, Kastan M.B. The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res 1994; 54: 5054-5058.
42. Chan C, Goldkorn T. Ceramide path in human lung cell death. Am J Respir Cell Mol Biol 2000; 22: 460-468.